Bayer Faces Billions in Payouts

As we usher in 2025, it’s the perfect time to prioritize health and wellness. Registered Dietitian and Nutritionist Kelly ...
Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...
In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.
Mit Blick auf die Neuausrichtung der Medikamentenpipeline von Bayer hatte Pharma-Chef Stefan Oelrich im letzten Januar ...
The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...
Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A ...